Treatment responses to integrase strand-transfer inhibitor-containing antiretroviral regimens in combination with short-course rifapentine-based regimens for latent tuberculosis infection among people with HIV
© The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissionsoup.com..
BACKGROUND: Real-world experience with combinations of short-course rifapentine-based regimens and integrase strand-transfer inhibitor (InSTI)-containing antiretroviral therapy (ART) in management of latent tuberculous infection (LTBI) is limited among people with HIV (PWH).
METHODS: From August 2019 to October 2022, PWH receiving 3 months of weekly rifapentine plus isoniazid (3HP) or 1 month of daily rifapentine plus isoniazid (1HP) in combination with ART were included. The primary outcome was virologic response within 12 months after LTBI treatment, and the secondary outcomes included treatment completion rate and safety of LTBI regimens.
RESULTS: During the study period, 479 PWH (94.6% male; median age, 43 years) were included: 142 received 1HP and bictegravir (BIC)-containing regimens (1HP/BIC group), 46 1HP and dolutegravir (DTG)-containing regimens (1HP/DTG group), 38 3HP and BIC-containing regimens (3HP/BIC group), 214 3HP and DTG-containing regimens (3HP/DTG group), 17 1HP and other ART regimens (1HP/others group), and 22 3HP/other ART regimens (3HP/others group). In the intention-to-treat analysis, the proportions of PWH maintaining plasma HIV-1 RNA <200 copies/mL within 12 months after LTBI treatment completion were 96.5% (1HP/BIC), 100% (1HP/DTG), 100% (3HP/BIC), 95.8% (3HP/DTG), 100% (1HP/others), and 100% (3HP/others). The overall completion rates were >80% for all treatment groups, whereas >50% of the included PWH experienced any adverse event. LTBI regimens and ART combinations were not associated with virologic response and completion rate.
CONCLUSION: Combinations of short-course rifapentine-based regimens and InSTI-containing ART maintained viral suppression for most PWH within 12 months of LTBI treatment completion with low rates of grade 3 or higher adverse events.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2023 |
|---|---|
| Enthalten in: |
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America - (2023) vom: 05. Dez. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Lin, Kuan-Yin [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Drug interaction |
|---|
| Anmerkungen: |
Date Revised 05.12.2023 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1093/cid/ciad730 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM365425885 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM365425885 | ||
| 003 | DE-627 | ||
| 005 | 20231226101636.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/cid/ciad730 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1218.xml |
| 035 | |a (DE-627)NLM365425885 | ||
| 035 | |a (NLM)38051646 | ||
| 035 | |a (PII)ciad730 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Lin, Kuan-Yin |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Treatment responses to integrase strand-transfer inhibitor-containing antiretroviral regimens in combination with short-course rifapentine-based regimens for latent tuberculosis infection among people with HIV |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 05.12.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a © The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissionsoup.com. | ||
| 520 | |a BACKGROUND: Real-world experience with combinations of short-course rifapentine-based regimens and integrase strand-transfer inhibitor (InSTI)-containing antiretroviral therapy (ART) in management of latent tuberculous infection (LTBI) is limited among people with HIV (PWH) | ||
| 520 | |a METHODS: From August 2019 to October 2022, PWH receiving 3 months of weekly rifapentine plus isoniazid (3HP) or 1 month of daily rifapentine plus isoniazid (1HP) in combination with ART were included. The primary outcome was virologic response within 12 months after LTBI treatment, and the secondary outcomes included treatment completion rate and safety of LTBI regimens | ||
| 520 | |a RESULTS: During the study period, 479 PWH (94.6% male; median age, 43 years) were included: 142 received 1HP and bictegravir (BIC)-containing regimens (1HP/BIC group), 46 1HP and dolutegravir (DTG)-containing regimens (1HP/DTG group), 38 3HP and BIC-containing regimens (3HP/BIC group), 214 3HP and DTG-containing regimens (3HP/DTG group), 17 1HP and other ART regimens (1HP/others group), and 22 3HP/other ART regimens (3HP/others group). In the intention-to-treat analysis, the proportions of PWH maintaining plasma HIV-1 RNA <200 copies/mL within 12 months after LTBI treatment completion were 96.5% (1HP/BIC), 100% (1HP/DTG), 100% (3HP/BIC), 95.8% (3HP/DTG), 100% (1HP/others), and 100% (3HP/others). The overall completion rates were >80% for all treatment groups, whereas >50% of the included PWH experienced any adverse event. LTBI regimens and ART combinations were not associated with virologic response and completion rate | ||
| 520 | |a CONCLUSION: Combinations of short-course rifapentine-based regimens and InSTI-containing ART maintained viral suppression for most PWH within 12 months of LTBI treatment completion with low rates of grade 3 or higher adverse events | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a drug interaction | |
| 650 | 4 | |a integrase strand-transfer inhibitor | |
| 650 | 4 | |a interferon-gamma release assay | |
| 650 | 4 | |a isoniazid | |
| 650 | 4 | |a rifamycin | |
| 700 | 1 | |a Sun, Hsin-Yun |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Chia-Jui |e verfasserin |4 aut | |
| 700 | 1 | |a Lu, Po-Liang |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Yuan-Ti |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Nan-Yao |e verfasserin |4 aut | |
| 700 | 1 | |a Liou, Bo-Huang |e verfasserin |4 aut | |
| 700 | 1 | |a Tang, Hung-Jen |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Mei-Hui |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Ning-Chi |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Tun-Chieh |e verfasserin |4 aut | |
| 700 | 1 | |a Hii, Ing-Moi |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Sung-Hsi |e verfasserin |4 aut | |
| 700 | 1 | |a Lin, Chi-Ying |e verfasserin |4 aut | |
| 700 | 1 | |a Tsai, Chin-Shiang |e verfasserin |4 aut | |
| 700 | 1 | |a Cheng, Chien-Yu |e verfasserin |4 aut | |
| 700 | 1 | |a Hung, Chien-Ching |e verfasserin |4 aut | |
| 700 | 0 | |a Taiwan HIV Study Group |e verfasserin |4 aut | |
| 700 | 1 | |a Hung, Chien-Ching |e investigator |4 oth | |
| 700 | 1 | |a Chang, Sui-Yuan |e investigator |4 oth | |
| 700 | 1 | |a Sun, Hsin-Yun |e investigator |4 oth | |
| 700 | 1 | |a Huang, Yu-Shan |e investigator |4 oth | |
| 700 | 1 | |a Lin, Kuan-Yin |e investigator |4 oth | |
| 700 | 1 | |a Chen, Guan-Jhou |e investigator |4 oth | |
| 700 | 1 | |a Wu, Pei-Ying |e investigator |4 oth | |
| 700 | 1 | |a Chen, Ling-Ya |e investigator |4 oth | |
| 700 | 1 | |a Chang, Hsi-Yen |e investigator |4 oth | |
| 700 | 1 | |a Liu, Wen-Chun |e investigator |4 oth | |
| 700 | 1 | |a Su, Yi-Ching |e investigator |4 oth | |
| 700 | 1 | |a Wang, Ning-Chi |e investigator |4 oth | |
| 700 | 1 | |a Lin, Te-Yu |e investigator |4 oth | |
| 700 | 1 | |a Yang, Chia-Jui |e investigator |4 oth | |
| 700 | 1 | |a Tsai, Mao-Song |e investigator |4 oth | |
| 700 | 1 | |a Lee, Mei-Hui |e investigator |4 oth | |
| 700 | 1 | |a Lee, Yi-Chieh |e investigator |4 oth | |
| 700 | 1 | |a Cheng, Shu-Hsing |e investigator |4 oth | |
| 700 | 1 | |a Cheng, Chien-Yu |e investigator |4 oth | |
| 700 | 1 | |a Liou, Bo-Huang |e investigator |4 oth | |
| 700 | 1 | |a Huang, Sung-Hsi |e investigator |4 oth | |
| 700 | 1 | |a Huang, Yi-Chia |e investigator |4 oth | |
| 700 | 1 | |a Peng, An-Ting |e investigator |4 oth | |
| 700 | 1 | |a Lee, Yuan-Ti |e investigator |4 oth | |
| 700 | 1 | |a Lee, Yu-Lin |e investigator |4 oth | |
| 700 | 1 | |a Lin, Chia-Chun |e investigator |4 oth | |
| 700 | 1 | |a Lin, Shih-Ping |e investigator |4 oth | |
| 700 | 1 | |a Hsieh, Chia-Yin |e investigator |4 oth | |
| 700 | 1 | |a Wang, Hsiu-Wen |e investigator |4 oth | |
| 700 | 1 | |a Ho, Mao-Wang |e investigator |4 oth | |
| 700 | 1 | |a Liu, Chun-Eng |e investigator |4 oth | |
| 700 | 1 | |a Hii, Ing-Moi |e investigator |4 oth | |
| 700 | 1 | |a Lin, Chi-Ying |e investigator |4 oth | |
| 700 | 1 | |a Tang, Hung-Jen |e investigator |4 oth | |
| 700 | 1 | |a Lee, Nan-Yao |e investigator |4 oth | |
| 700 | 1 | |a Tsai, Chin-Shiang |e investigator |4 oth | |
| 700 | 1 | |a Hung, Tung-Che |e investigator |4 oth | |
| 700 | 1 | |a Chen, Yen-Hsu |e investigator |4 oth | |
| 700 | 1 | |a Lu, Po-Liang |e investigator |4 oth | |
| 700 | 1 | |a Lee, Chun-Yuan |e investigator |4 oth | |
| 700 | 1 | |a Chen, Tun-Chieh |e investigator |4 oth | |
| 700 | 1 | |a Tsai, Hung-Chin |e investigator |4 oth | |
| 700 | 1 | |a Lin, Hsi-Hsun |e investigator |4 oth | |
| 700 | 1 | |a Lee, Chen-Hsiang |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical infectious diseases : an official publication of the Infectious Diseases Society of America |d 1992 |g (2023) vom: 05. Dez. |w (DE-627)NLM012603007 |x 1537-6591 |7 nnns |
| 773 | 1 | 8 | |g year:2023 |g day:05 |g month:12 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/cid/ciad730 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2023 |b 05 |c 12 | ||